Published in Clin Exp Immunol on March 01, 1998
Specific immunotherapy of experimental myasthenia gravis by a novel mechanism. Ann Neurol (2010) 1.53
Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest (1999) 0.95
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest (1999) 0.87
Modulating phenotype and cytokine production of leucocytic retinal infiltrate in experimental autoimmune uveoretinitis following intranasal tolerance induction with retinal antigens. Br J Ophthalmol (1999) 0.83
Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. Clin Exp Immunol (2000) 0.80
Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag (2011) 0.77
Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats. J Clin Immunol (2003) 0.76
Vaccines against myasthenia gravis. Expert Opin Biol Ther (2005) 0.76
A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146. Front Immunol (2017) 0.75
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today (1996) 12.12
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science (1990) 7.18
Myasthenia gravis. N Engl J Med (1994) 5.11
Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 4.93
Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem (1972) 4.87
Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol (1990) 2.79
Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today (1997) 2.44
Towards a comprehensive view of immunoglobulin class switching. Immunol Today (1993) 2.44
Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature (1984) 2.18
The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods (1988) 1.92
Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science (1977) 1.91
Production and assay of antibodies to acetylcholine receptors. Methods Enzymol (1981) 1.73
Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol (1992) 1.73
Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol (1994) 1.72
Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J Immunol (1987) 1.66
Molecular cloning of rat interleukin 4 cDNA and analysis of the cytokine repertoire of subsets of CD4+ T cells. Eur J Immunol (1991) 1.62
Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci (1976) 1.43
Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass. Eur J Immunol (1996) 1.36
Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. Eur J Immunol (1993) 1.24
The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Eur J Biochem (1996) 1.24
Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med (1997) 1.22
Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction. J Exp Med (1995) 1.17
Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol (1995) 1.17
Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol (1993) 1.15
Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest (1991) 1.10
In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression. Eur J Immunol (1994) 1.09
Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol (1999) 1.07
Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol (1994) 1.07
Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol (1991) 1.02
Cloning, expression, and purification of rat IFN-gamma. Methods Enzymol (1986) 1.00
Generation of B cell memory and affinity maturation. Induction with Th1 and Th2 T cell clones. J Immunol (1992) 1.00
Evidence for functional heterogeneity of rat CD4+ T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipients of cardiac allografts. J Immunol (1992) 0.95
Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis. J Immunol (1988) 0.93
Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology (1994) 0.92
Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J Neuroimmunol (1985) 0.87
Altered Th1/Th2 balance associated with non-major histocompatibility complex genes in collagen-induced arthritis in resistant and non-resistant rat strains. Eur J Immunol (1997) 0.87
Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin Immunol Immunopathol (1993) 0.87
Induction of interferon-gamma, interleukin-4, and transforming growth factor-beta in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol (1994) 0.87
Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J Neuroimmunol (1996) 0.85
Binding of monomeric immunoglobulins by bone marrow-derived mononuclear phagocytes; its modulation by interferon-gamma. Eur J Immunol (1990) 0.84
Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin Immunol Immunopathol (1991) 0.84
Response to human acetylcholine receptor alpha 138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett (1994) 0.83
Characterization of anti-acetylcholine receptor (AChR) antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis (EAMG). Clin Exp Immunol (1993) 0.83
Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve (1996) 0.81
T-cell immunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis. Scand J Immunol (1993) 0.80
Cellular mRNA expression of interferon-gamma (IFN-gamma), IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats. Clin Exp Immunol (1997) 0.80
'Split tolerance' induction by intrathymic injection of acetylcholine receptor in a rat model of autoimmune myasthenia gravis; implications for the design of specific immunotherapies. Clin Exp Immunol (1995) 0.77
Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv Neuroimmunol (1994) 0.76
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler (1999) 4.91
Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest (1977) 4.63
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med (1997) 3.59
COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem (1996) 3.17
Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol (1971) 2.51
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer (2004) 2.03
Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest (1977) 2.02
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer (2006) 1.96
TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol (1999) 1.95
TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med (2000) 1.90
Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain (2001) 1.78
The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol (2005) 1.77
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol (1991) 1.65
Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. J Immunol Methods (1985) 1.62
Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol (2000) 1.61
Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest (1990) 1.57
Early diagnosis of tuberculous meningitis by detection of anti-BCG secreting cells in cerebrospinal fluid. Lancet (1990) 1.55
Effect of vacuolar proton ATPase on pHi, Ca2+, and apoptosis in neonatal cardiomyocytes during metabolic inhibition/recovery. Circ Res (1998) 1.53
Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology (1998) 1.53
Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. J Exp Med (1999) 1.49
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun (1999) 1.48
Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun (1974) 1.48
Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience (2000) 1.47
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 1.45
Duration of breast-feeding and the incidence of type 2 diabetes mellitus in the Shanghai Women's Health Study. Diabetologia (2007) 1.45
Measles virus antibodies in multiple sclerosis. Comparison of antibody titers in cerebrospinal fluid and serum. Arch Neurol (1974) 1.44
Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest (1998) 1.44
Treatment with gamma-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum (1988) 1.44
The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J Neurol Sci (1994) 1.43
Multiple myeloma presenting with acute disseminated encephalomyelitis: causal or chance link? Neurology (2006) 1.42
Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol (2000) 1.40
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol (1996) 1.40
Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol (1973) 1.40
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
The elongation factor EF-Tu and its two encoding genes. Prog Nucleic Acid Res Mol Biol (1983) 1.37
Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol (1991) 1.36
Immunoglobulins and measles antibodies in subacute sclerosing panencephalitis. Arch Neurol (1973) 1.35
Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol (1994) 1.33
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (2000) 1.31
Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res (1996) 1.30
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol (2001) 1.30
Cruciferous vegetables intake and the risk of colorectal cancer: a meta-analysis of observational studies. Ann Oncol (2012) 1.29
Cerebrospinal fluid and serum immunoglobulins and antibody titers in mumps meningitis and aseptic meningitis of other etiology. Infect Immun (1978) 1.28
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology (1998) 1.26
Innovative mentoring programs to promote gender equity in academic medicine. Acad Med (2001) 1.23
Immunoglobulins and measles antibodies in optic neuritis. N Engl J Med (1973) 1.22
Mutants of Escherichia coli altered in both genes coding for the elongation factor Tu. Proc Natl Acad Sci U S A (1978) 1.22
CD16- CD56+ natural killer cells after bone marrow transplantation. Blood (1992) 1.21
Characterization of antibody activity in oligoclonal immunoglobulin G synthesized within the central nervous system in a patient with tuberculous meningitis. J Clin Microbiol (1981) 1.20
Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol (2004) 1.18
Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke (1999) 1.18
Multiple sclerosis: disturbed kappa: lambda chain ratio of immunoglobulin G in cerebrospinal fluid. Clin Exp Immunol (1970) 1.18
Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A (1994) 1.18
IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17
Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest (1977) 1.17
Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol (1990) 1.17
Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol (1995) 1.17
Respiratory syncytial virus stimulation of vascular endothelial cell growth Factor/Vascular permeability factor. Am J Respir Cell Mol Biol (2000) 1.17
Comparison of electrophoresis on agar gel and agarose gel in the evaluation of gamma-globulin abnormalities in cerebrospinal fluid and serum in multiple sclerosis. Clin Chim Acta (1973) 1.17
Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol (1997) 1.16
Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci (2000) 1.16
Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol (1993) 1.15
Bidirectional activating signals between Trypanosoma brucei and CD8+ T cells: a trypanosome-released factor triggers interferon-gamma production that stimulates parasite growth. Eur J Immunol (1991) 1.14
B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J Exp Med (2001) 1.13
Persistence of tropical ataxic neuropathy in a Nigerian community. J Neurol Neurosurg Psychiatry (2000) 1.13
Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem (1984) 1.12
Age-specific prevalence of antibody to enterotoxigenic Escherichia coli in Ecuadorian and German children. J Infect Dis (1990) 1.12
Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol (1991) 1.11
Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol (2001) 1.11
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol (2013) 1.11
CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand (1987) 1.10
Polymorphism in Plasmodium vivax MSA1 gene--the result of intragenic recombinations? Parasitology (1993) 1.10
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol (2011) 1.08
Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol (1999) 1.07
Aedes (Stegomyia) bromeliae (Diptera: Culicidae), the yellow fever virus vector in East Africa. J Med Entomol (1986) 1.07
Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol (1994) 1.07
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol (1996) 1.07
Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors: comment. J Thromb Haemost (2014) 1.07
Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol (1992) 1.07
Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol (1999) 1.06
Atomic force microscopy study of fine structures of the entire surface of red blood cells. Scanning Microsc (1995) 1.06
Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.05
Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1980) 1.05
Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis (1990) 1.05
Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol (1998) 1.04
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol (2001) 1.04